-
GlaxoSmithKline PLC has said that it expects to be able to fill government orders for swine-flu vaccines by early 2010, but the company"s chief executive said production was going slower because the vaccine has yielded low levels of antigen, the ingredient that causes an immune response.Zanamivir the active ingredient in Relenza,will be in production over the next six months to replace supplies w
제약단신
메디칼라이터팀
2009.07.23 00:00
-
GlaxoSmithKline posted an 11 percent rise in second quarter profit due to its sales in emerging markets. The company, the second largest by revenue, has contracts for 195 million doses of swine flu vaccine and expects to make $2.1 billion in sales next year but still the company struggles to maintain margins after loss of patents. The outbreak has claimed 31 lives in Britain but CEO Andrew Witty m
제약단신
메디칼라이터팀
2009.07.23 00:00
-
The World Health Organization (WHO) said studies that were published in the journal, PLoS Neglected Tropical Diseases, showed that reatment with the drug ivermectin stopped further infections and transmission of river blindness in three areas of Africa in Mali and Senegal. Around 37 million people are infected which leads to loss of sight and the development of painful skin complaints. The drug, d
제약단신
메디칼라이터팀
2009.07.23 00:00
-
An Australian pharmaceutical company, will begin its experimental swine flu vaccine trials at Royal Adelaide Hospital on 240 volunteers between the ages of 18 and 64. Dr. Russell Basser, the company"s global director of clinical development, has said that depending on the properties of the influenza, patients may need higher dosing to get the desired immune response.
제약단신
메디칼라이터팀
2009.07.23 00:00
-
Johnson & Johnson might become Elan Corp."s partner on the multiple sclerosis drug Tysabri [natalizumab], replacing Biogen Idec Inc. following an agreement both J&J and Biogen have that if one of them is aquired the other has the rights to Tsyabri.
제약단신
메디칼라이터팀
2009.07.23 00:00
-
Data from the first human trial presented at the International AIDS Society"s conference in Cape Town, South Africa, showed GlaxoSmithKline PLC"s experimental AIDS drug, S/GSK1349572, decreased the virus to undetectable levels in 70 percent of the 35 patients in the study and none of the patients showed signs of drug resistance.
제약단신
메디칼라이터팀
2009.07.23 00:00
-
The development of new AIDS vaccines in South Africa may be threatened after South Africa"s Department of Science and Technology retracted funds from the vaccine project in March last year which was aimed at creating the first vaccine in a country with the world"s highest number of infections.
제약단신
메디칼라이터팀
2009.07.22 00:00
-
"U,S News & World Report"가 올해 미국 내 최고의 병원들에 대한 "Honor Roll"을 발표했다. 올해 1위는 존스홉킨스병원(Johns Hopkins Hospital)으로 19회 연속 1위에 오르는 기염을 토했다. 채점 기준은 사망률, 환자의 만족도, 진료관계 요소 등 객관적인 수치들과 함께 병원의 명성 등 주관적인 인식도도 반영했다. "U,S News & World Report"는 이번 순위가 작은 규모의 사람들을 대상으로 조사했지만, 높은 수준의 의료서비스를 원하는 소수에게는 의미있는 자료가 될 것이라고 밝혔다. 이와함께 이번 순위가 일반적인 치료를 받는 사람들 모두에게 영향을 주는 것은 아니라는 점을 명확히 했다. 미국병원협회(American Hospital Ass
제약단신
임세형 기자
2009.07.22 00:00
-
미국식품의약국(FDA)이 2009~2010년 계절성 인플루엔자(influenza) 백신을 승인했다. FDA는 올해 A/Brisbane/59/2007(H1N1), A/Brisbane/10/2007(H3N2), B/Brisbane/60/2008와 유사한 유형의 바이러스가 유행할 것으로 예상했다. 백신으로는 GSK의 플루아릭스(Fluarix), 노바티스(Novartis)의 플루비린(Fluvirin), 사노피파스퇴르(Sanofi Pasteur)의 플루존(fluzone) 등이 시판될 예정이다. FDA는 이번 계절성 인플루엔자 백신이 신종 인플루엔자(신종플루) 예방에는 효과가 없지만 계절성 인플루엔자의 위험도를 간과해서는 안된다고 강조했다. 미국질병통제예방센터(CDC)에 의하면 매년 계절성 인플루엔자 합병증으로 인해
제약단신
임세형 기자
2009.07.22 00:00
-
Following analyses of past clinical trials label information on the cancer treatment Erbitux [cetuximab] will now say there is no evidence the drug works on a minority of colon cancer patients with a specific genetic mutation. According to drugmakers Eli Lilly & Co. and Bristol-Myers Squibb Co, the addition will state that research has not indicated that Erbitux helps patients whose tumors have a
제약단신
메디칼라이터팀
2009.07.21 00:00
-
Wyeth shareholders approved a takeover by Pfizer Inc., helping to lay the groundwork for the deal to close this year although certain animal-health assets need to be disposed of before it is approved by European and US Regulators as both companies have overlapping businesses.
제약단신
메디칼라이터팀
2009.07.21 00:00
-
A group of researchers and government officials spanning Africa, Asia and the United States together with Interpol, the international police agency, are trying to track fake drugs and in particular, Malaria drugs using cutting-edge technology. The concern is that the fakes are contributing to the growing problem of resistance. By tracing pollen grains in the drugs or packaging researchers have est
제약단신
메디칼라이터팀
2009.07.21 00:00
-
In late stage clinical trials patients who took Orexigen Therapeutics Inc."s Contrave had significantly greater weight loss than those who took a placebo, and the drug reduced other risk factors like waist circumference. FDA testing guidelines require a third of patients to lose 5 percent of body weight. this was achieved in two trials of non-diabetic patients and the other trial showed that Cont
제약단신
메디칼라이터팀
2009.07.21 00:00
-
According to the GAO, the FDA doesn"t have the data to develop a complete and reliable estimate of the resources it needs although Dr. Joshua Sharfstein, FDA deputy commissioner, has said that more detail is needed when talking about the purpose of the funds and how much more is needed but this will take time in order to get to the level of detail that people want.The GAO has also said that the F
제약단신
메디칼라이터팀
2009.07.21 00:00
-
In a study of 724 patients who received 100 to 200 milligrams a day of thalidomide or the placebo for up to two years, the median overall survival for patients in the thalidomide group was 10.1 months, compared to 10.5 months for those in the placebo group. Those on the drug increased their risk of blood clots. According to researchers, there is a need to take a new look at the basic biology of sm
제약단신
메디칼라이터팀
2009.07.20 00:00
-
Shionogi & Co., a Japanese drugmaker, said its experimental, intravenous influenza drug, peramivir, was shown to be as effective as Roche Holding AG"s Tamiflu [oseltamivir], in the last stage of testing required for regulatory approval. The drug was shown to relieve symptoms of seasonal influenza. The company will submit its data to Japan"s health ministry for approval of the drug this year.
제약단신
메디칼라이터팀
2009.07.20 00:00
-
Pharmaceutical companies doing business in the Philippines offered to halve the prices of more than 80 best-selling drugst in order to dissuade President Gloria Macapagal Arroyo from imposing price controls on essential medicines. According to Alexander Padilla, a health department undersecretary, the Philippine operations of 14 global drug companies, including Pfizer, have made submissions regard
제약단신
메디칼라이터팀
2009.07.20 00:00
-
The FDA has issued a draft clarifying how it plans to regulate drug additives that are intended to deter counterfeiting making it easier for authorities, providers, and consumers to spot fake prescription drugs. The FDA recommends that additives not be allergenic or used at unsafe levels, regulations that are considered unsurprising.
제약단신
메디칼라이터팀
2009.07.20 00:00
-
A weight-loss and skin-care company, along with the Food and Drug Administration, recalled hundreds of weight-loss pills after the agency found that four dietary supplements contained the ingredient, sibutramine. The recalled products include Slimbionic, One Weight Loss Pill, SlimDemand Capsules and Botanical Weight Loss, all of which are sold in boxes containing 30 capsules. While no injuries hav
제약단신
메디칼라이터팀
2009.07.20 00:00
-
In Phase III trials 865 patients located in 13 countries outside the United States were given different doses of Benlysta (belimumab), or a placebo, for a one-year period. Of patients receiving the placebo 44 percent experienced meaningful improvement in their symptoms whereas 58 percent of those having high dose Benlysta saw improvement and 52 percent having low dose improved. Benlysta is given i
제약단신
메디칼라이터팀
2009.07.20 00:00